Language Selection

English French German Italian Portuguese Spanish

Premarket Movers: Novell Down After Deal

Filed under

Microsoft Corp.'s support agreement with Novell Inc. dominated the early session, with investors trying to sort out the winners and losers of the industry-shaking deal.

Shareholders initially punished Novell, sending its stock down ahead of the bell even after Microsoft, in essence, gave its stamp of approval to Novell's version of the open-source operating software Linux over competitor Red Hat Inc.'s.

"Microsoft is signaling a preference to prop up the market laggard in the Linux market to the detriment of Red Hat," said Sun Trust analyst Terry Tillman.

But the analyst doesn't expect Novell to benefit necessarily. "Importantly, we believe this partnership does nothing to stem Novell's NetWare declines nor Microsoft's focus on impairing Novell's growth prospects," Tillman wrote.

Novell shares lost as much as 23 cents, or 3.4 percent to $6.56 in premarket electronic trading before shares recovered, matching their Thursday close at $6.79 on the Nasdaq. In the past year, the stock has ranged from $5.73 to $9.83.

Microsoft shares rose 6 cents to $28.83. The company will be able to offer support for both its proprietary Windows operating system and Novell's Linux system as part of the deal, which could expand its corporate customer base. The software company's shares closed Thursday at $28.77 on the Nasdaq.

Meanwhile, Red Hat, which provides a different version of Linux than Novell, saw its shares drop on the news. Baird analyst Steven Ashley downgraded the stock to "Neutral," from "Outperform," saying there is "simply too much near-term noise and uncertainty" in the open-source market.

Red Hat lost as much as 50 cents, or 3 percent, before regaining some ground. Shares were lately down 21 cents, to $15.89 in off-hours trading. The stock closed Thursday at $16.10 on the Nasdaq, where it has ranged from $13.70 to $32.48 in the past year.

Leaving software for pharmaceuticals, Inspire Pharma Inc. shot up ahead of the bell after reporting that its drug to treat cystic fibrosis was "well tolerated" in a Phase II clinical trial.

"There were no serious adverse events or patient withdrawals during the trial," the company said in a statement. The next step is to enroll patients in a Phase III trial to test effectiveness.

Cystic fibrosis is a hereditary lung and digestive system disease that affects about 30,000 children in the United States, according to the Cystic Fibrosis Foundation.

Inspire shares added 42 cents, or 7.9 percent, to $5.71 in the early session after closing Thursday at $5.29 on the Nasdaq. In the past year, Inspire has ranged from $3.92 to $7.88.

Shares in Encysive Pharmaceuticals Inc. rose before the bell after the drug maker said it responded to regulators who requested more information about the company's Thelin hypertension drug.

The Food and Drug Administration said it needed the information before it could make a decision on whether to approve Thelin.

Investors, who had punished Encysive in July when the FDA requested the information, cheered the move, sending the stock up 77 cents, or 15 percent, to $5.90 in electronic premarket trading. The shares closed Thursday at $5.13 on the Nasdaq, where they have ranged from $3.29 to $11.64 in the past year.

Associated Press

More in Tux Machines

Clonezilla Live 2.4.2-59 Arrives with Updated Debian Base

Clonezilla Live, a Linux distribution based on DRBL, Partclone, and udpcast, which allows users to do a lot of maintenance and recovery work, is now at version 2.4.2-59 and is available for download and testing. Read more

Running Some Fresh BSD vs. Linux Benchmarks

Given the recent releases of FreeBSD 10.2 and NetBSD 7.0, plus the H2'2015 Linux distribution updates rolling around, I've just started work on a new BSD vs. Linux operating system performance comparison. First up are the BSD distributions for testing... The test system being used for this comparison is an Intel Xeon E5-2687W v3 Haswell-E plus AMD FirePro system. Given the new release of NetBSD 7.0, I decided to try that out first. Read more

Android 6.0 Marshmallow review

Android, Google’s mobile operating system, has matured a lot over the past year. It’s running on 1.4 billion devices (up from 1 billion last year) and its most popular app store, Google Play, has more than 1 billion active users. In the last quarter, IDC estimates that Android held 82.8 percent of the global smartphone market. As its newest iteration, 6.0 Marshmallow, rolls out, Android’s going incredibly, undeniably strong. Read more

At the Heart of OpenStack Evolution

As it matures, OpenStack's parallel to Linux is clearer. Linux emerged 20 years ago as a somewhat exotic challenger to proprietary operating systems. Today, it is one of the most popular and widely used OSes. However, Linux still exists in a market of mixed use. It's likely that OpenStack will be subject to the same effect, becoming a viable option among a number of cloud infrastructures. Read more